A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Study Details
Study Description
Brief Summary
This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Trastuzumab Emtansine Participants will receive trastuzumab emtansine either as a single agent or in combination with other anti-cancer therapy (atezolizumab, paclitaxel, trastuzumab and docetaxel). Participants will receive the same dose and schedule on Cycle 1, Day 1 at which it was given at the end of the parent study. Study drug will be administered in 21-day cycles or weekly, depending on the schedule used in the parent study. Participants will receive study treatment until disease progression or unacceptable toxicity. |
Drug: Docetaxel
Docetaxel will be administered as per local prescribing information.
Drug: Paclitaxel
Paclitaxel will be administered as per local prescribing information.
Drug: Pertuzumab
Pertuzumab will be administered intravenously at a dose of 420 milligrams (mg) no more frequently than every 3 weeks (Q3W) (or as directed in the parent study protocol if less than Q3W).
Other Names:
Drug: Trastuzumab
Trastuzumab will be administered as per local prescribing information.
Other Names:
Drug: Trastuzumab Emtansine
Trastuzumab emtansine will be administered as intravenous (IV) infusion. Participants on weekly dosing schedule of trastuzumab emtansine in parent study, may switch to Q3W schedule as per the clinical judgment of the investigator. The starting dose of Q3W schedule must not exceed 3.6 milligrams per kilograms (mg/kg).
Other Names:
Drug: Atezolizumab
Atezolizumab will be administered at a dose of 1200 mg by IV infusion every three weeks (Q3W)
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [Baseline up to 30 days after last dose of study drug administration (up to approximately 14 years)]
- Percentage of Participants With Adverse Events Leading to Study Treatment Discontinuation or Dose Reduction [Baseline up to 30 days after last dose of study drug administration (up to approximately 14 years)]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Completed single-agent trastuzumab emtansine or combination trastuzumab emtansine treatment in the parent study or who continue to receive single-agent trastuzumab emtansine or combination trastuzumab emtansine treatment at the time of the parent study closure and received the last study drug dose within the 6 weeks (42 days) prior to the first dose of study therapy on the extension study or Continue to receive treatment in the control arm of study BO21976/TDM4450g (NCT00679341) at the time of the parent study closure if the participant received the last dose of control arm study drug within the 6 weeks (42 days) prior to the first dose of control arm study therapy in the extension study
-
Participants in the control arm from Study BO21976/TDM4450g whose disease progression has occurred during the transition interval between the parent study and this extension study may initiate trastuzumab emtansine treatment at the time of enrollment into study TDM4529g (NCT00781612)
-
Expectation by the investigator that the participant may continue to benefit from additional single-agent trastuzumab emtansine or combination trastuzumab emtansine treatment or Expectation of the investigator that the participant may continue to benefit from control arm treatment as given in study BO21976/TDM4450g and at the time of disease progression may benefit from single-agent trastuzumab emtansine treatment
-
Women of childbearing potential and men with partners of childbearing potential, must be willing to use a highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception by the participants and/or partner, and to continue the use of contraception for the duration of study treatment and for at least 5 months after the final dose of atezolizumab (if applicable) or 7 months after the final dose of trastuzumab emtansine or pertuzumab, whichever is later. Women must refrain from donating eggs during this same period
-
Male participants whose partners are pregnant should use condoms for the duration of the pregnancy. Men must refrain from donating sperm during this same period
Exclusion Criteria:
-
AEs leading to single-agent trastuzumab emtansine or combination trastuzumab emtansine treatment discontinuation in the parent study
-
Ongoing SAEs from the parent study
-
Progressive disease on single-agent trastuzumab emtansine or a trastuzumab emtansine-containing regimen during the parent study or before starting the extension study, with the exception of participants from study TDM4688g (NCT00943670) with early disease progression who went on to receive pertuzumab + trastuzumab emtansine treatment and have not experienced further disease progression on the combination regimen
-
Peripheral neuropathy of Grade greater than or equal to (>/=) 3 per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0, 4.0 or 5.0, as utilized in the parent study
-
History of symptomatic congestive heart failure ([CHF]; New York Heart Association [NYHA] Classes II-IV), ventricular arrhythmia requiring treatment, current unstable angina, or history of myocardial infarction within 6 months prior to study entry
-
Severe dyspnea at rest due to complications of advanced malignancy or current requirement for continuous oxygen therapy
-
Current severe, uncontrolled systemic disease (for example [e.g.] clinically significant cardiovascular, pulmonary, or metabolic disease)
-
Major surgical procedure or significant traumatic injury within 28 days prior to study entry or anticipation of the need for major surgery during the course of study treatment
-
Current pregnancy or lactation
-
History of receiving any investigational treatment or other systemic therapy directed at controlling cancer (e.g., chemotherapy, trastuzumab, etc.) since the participant's last study drug dose in the parent study
-
History of hypersensitivity with previous trastuzumab emtansine or any agent used with trastuzumab emtansine in the parent study, precluding further dosing
-
Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | City of Hope National Medical Center | Duarte | California | United States | 91010 |
2 | Can Care Assoc Med Group Inc; Beach Cities Offices | Los Angeles | California | United States | 90095-1772 |
3 | Comp Cancer Centers of Nevada | Los Angeles | California | United States | 90095-1772 |
4 | Univ of Calif, San Francisco; Breast Cancer Center | San Francisco | California | United States | 94115 |
5 | Central Coast Medical Oncology | Santa Maria | California | United States | 93454 |
6 | UCLA Oncology Office; Oncology | Santa Monica | California | United States | 90404 |
7 | Stanford Cancer Institute | Stanford | California | United States | 94305 |
8 | Kaiser Permanente; Oncology Clinical Trials | Vallejo | California | United States | 94589 |
9 | Kaiser Permanente - Walnut Creek | Walnut Creek | California | United States | 94596 |
10 | Univ of Colorado Canc Ctr | Aurora | Colorado | United States | 80045 |
11 | University of Colorado | Aurora | Colorado | United States | 80045 |
12 | Rocky Mountain Cancer Center - Denver | Littleton | Colorado | United States | 80120 |
13 | Christina Care Institutional Review Board | Newark | Delaware | United States | 18713 |
14 | Florida Cancer Specialists; Department of Oncology | Fort Myers | Florida | United States | 33901-8101 |
15 | Baptist - MD Anderson Cancer Center | Jacksonville | Florida | United States | 32207 |
16 | Univ of Miami Health Systems | Miami | Florida | United States | 33136 |
17 | Memorial Cancer Institute at Memorial West | Pembroke Pines | Florida | United States | 33028 |
18 | Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building) | Saint Petersburg | Florida | United States | 33705 |
19 | Florida Cancer Specialists - Tampa (Dr. MLK Blvd) | Tampa | Florida | United States | 33607 |
20 | Northwest Georgia Oncology Centers PC - Marietta | Marietta | Georgia | United States | 30060 |
21 | Kootenai Cancer Center | Post Falls | Idaho | United States | 83854 |
22 | Loyola University Med Center | Maywood | Illinois | United States | 60153 |
23 | Illinois Cancer Care | Peoria | Illinois | United States | 61615 |
24 | Midwestern Regional Medical Center; Office of Research | Zion | Illinois | United States | 60099 |
25 | Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | United States | 46202 |
26 | Hematology-Oncology; Associates of the Quad Cities | Bettendorf | Iowa | United States | 52722 |
27 | Oncology Assoc of Cedar Rapids; Iowa Cancer Care | Cedar Rapids | Iowa | United States | 52403 |
28 | Cancer Center of Kansas | Wichita | Kansas | United States | 67214-3728 |
29 | New England Cancer Specialists | Scarborough | Maine | United States | 04074 |
30 | Anne Arundel Medical Center; Anne Arundel Health System | Annapolis | Maryland | United States | 21401 |
31 | Johns Hopkins Univ Med Center | Baltimore | Maryland | United States | 21231 |
32 | Massachusetts General Hospital | Boston | Massachusetts | United States | 02114 |
33 | Dana Farber Cancer Institute; Breast Oncology | Boston | Massachusetts | United States | 02115 |
34 | Karmanos Cancer Institute | Detroit | Michigan | United States | 48201 |
35 | Minnesota Oncology Hematology, Pa | Minneapolis | Minnesota | United States | 55407 |
36 | University of Minnesota. | Minneapolis | Minnesota | United States | 55454 |
37 | Mayo Clinic - Rochester | Rochester | Minnesota | United States | 55905 |
38 | Capitol Comprehensive CA Care | Jefferson City | Missouri | United States | 65101 |
39 | St. John's Mercy Medical Ctr; David C. Pratt Cancer Center | Saint Louis | Missouri | United States | 63141 |
40 | Mercy Clinic Cancer & Hematology | Springfield | Missouri | United States | 65804 |
41 | St. Barnabas Health Care Sys | Livingston | New Jersey | United States | 07039 |
42 | NS-Long Island Jewish Hlth Sys | Lake Success | New York | United States | 11042 |
43 | Laura and ISAAC Perlmutter Cancer Center at NYU Langone. | New York | New York | United States | 10016 |
44 | Memorial Sloan-Kettering Cancer Center | New York | New York | United States | 10065 |
45 | Clinical Research Alliance | Westbury | New York | United States | 11590 |
46 | Carolina Oncology Specialists, PA - Hickory | Hickory | North Carolina | United States | 28602 |
47 | The Cleveland Clinic Foundation | Cleveland | Ohio | United States | 44195 |
48 | The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc. | Columbus | Ohio | United States | 43219 |
49 | Northwest Cancer Specialists - Portland (N Broadway) | Portland | Oregon | United States | 97227 |
50 | Fox Chase Cancer Center | Philadelphia | Pennsylvania | United States | 19111 |
51 | SCRI Tennessee Oncology Chattanooga | Chattanooga | Tennessee | United States | 37404 |
52 | Sarah Cannon Cancer Center | Germantown | Tennessee | United States | 38138 |
53 | Vanderbilt Ingram Cancer Ctr | Nashville | Tennessee | United States | 37232 |
54 | Texas Oncology | Bedford | Texas | United States | 76022 |
55 | Texas Oncology - Dallas Presbyterian Hospital | Dallas | Texas | United States | 75231 |
56 | Millennium Research & Clinical Development | Houston | Texas | United States | 77090 |
57 | US Oncology Research Pharm. | Irving | Texas | United States | 75063 |
58 | US Oncology | Irving | Texas | United States | 75063 |
59 | USO | Plano | Texas | United States | 75075-7787 |
60 | Cancer Therapy & Research Center | San Antonio | Texas | United States | 78229 |
61 | US Oncology Research, Inc. | The Woodlands | Texas | United States | 77380 |
62 | USO - Tyler Cancer Ctr | Tyler | Texas | United States | 75702 |
63 | Univ of WA Medical Center | Seattle | Washington | United States | 98109 |
64 | Uni of Washington Medical Center; Dept of Oncology | Seattle | Washington | United States | 98195 |
65 | Northwest Medical Specialties | Tacoma | Washington | United States | 98405 |
66 | Peninsula and South Eastern Haematology and Oncology Group | Frankston | Victoria | Australia | 3199 |
67 | Peter MacCallum Cancer Center | North Melbourne | Victoria | Australia | 3051 |
68 | Klinik Favoriten; 1 Medizinische Abteilung | Wien | Austria | 1100 | |
69 | UZ Gent | Gent | Belgium | 9000 | |
70 | Sint Augustinus Wilrijk, Apotheek | Wilrijk | Belgium | 2610 | |
71 | Nucleo de Oncologia da Bahia - NOB | Salvador, Bahia | BA | Brazil | 40170-380 |
72 | Trymed Clinical Research | Belo Horizonte | MG | Brazil | 30150-281 |
73 | Instituto Nacional de Cancer - INCa; Oncologia | Rio de Janeiro | RJ | Brazil | 20560-120 |
74 | Santa Casa de Misericordia de Porto Alegre | Porto Alegre | RS | Brazil | 90050-170 |
75 | Clinica de Oncologia de Porto Alegre - CliniOnco | Porto Alegre | RS | Brazil | 90430-090 |
76 | Hospital Sao Lucas - PUCRS | Porto Alegre | RS | Brazil | 90610-000 |
77 | Hospital Nossa Senhora da Conceicao | Porto Alegre | RS | Brazil | 91350-200 |
78 | Clinica de Neoplasias Litoral | Itajai | SC | Brazil | 88301-220 |
79 | Faculdade de Medicina do ABC - FMABC; Oncologia e Hematologia | Santo Andre | SP | Brazil | 09060-650 |
80 | Hospital Perola Byington | Sao Paulo | SP | Brazil | 01317-000 |
81 | Complex Oncology Center - Plovdiv First Internal Chemotherapy Department | Plovdiv | Bulgaria | 4004 | |
82 | SHATO - Sofia | Sofia | Bulgaria | 1756 | |
83 | BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre) | Kelowna | British Columbia | Canada | V1Y 5L3 |
84 | Ottawa Regional Cancer Centre; Civic Hospital Division | Ottawa | Ontario | Canada | K1H 8L6 |
85 | St. Michael'S Hospital | Toronto | Ontario | Canada | M5B 1W8 |
86 | University Health Network; Princess Margaret Hospital; Medical Oncology Dept | Toronto | Ontario | Canada | M5G 2M9 |
87 | Centre Hospitalier de l'Université de Montréal (CHUM) | Montreal | Quebec | Canada | H2X 0C2 |
88 | Saskatoon Cancer Centre | Saskatoon | Saskatchewan | Canada | SK S7N 4H4 |
89 | CHU de Québec - Hôpital du Saint-Sacrement / ONCOLOGY | Quebec | Canada | G1S 4L8 | |
90 | Fundacion Arturo Lopez Perez | Santiago | Chile | 7500921 | |
91 | Beijing Cancer Hospital | Beijing | China | 100142 | |
92 | Sun Yet-sen University Cancer Center | Guangzhou | China | 510060 | |
93 | Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department | Hangzhou City | China | 310022 | |
94 | Harbin Medical University Cancer Hospital | Harbin | China | 150081 | |
95 | Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University) | Nanjing City | China | 210029 | |
96 | Jiangsu Cancer Hospital | Nanjing City | China | 211100 | |
97 | Fudan University Shanghai Cancer Center | Shanghai City | China | 200120 | |
98 | Clinical Hospital Centre Zagreb | Zagreb | Croatia | 10000 | |
99 | Masarykuv onkologicky ustav | Brno | Czechia | 656 53 | |
100 | Fakultni nemocnice Olomouc; Onkologicka klinika | Olomouc | Czechia | 779 00 | |
101 | Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika | Praha 2 | Czechia | 128 08 | |
102 | Odense Universitetshospital, Onkologisk Afdeling R | Odense C | Denmark | 5000 | |
103 | Vejle Sygehus; Onkologisk Afdeling | Vejle | Denmark | 7100 | |
104 | Centre Francois Baclesse; Comite Sein | Caen | France | 14076 | |
105 | Centre Georges Francois Leclerc; Oncologie 3 | Dijon | France | 21079 | |
106 | Centre Hospitalier Departemental Les Oudairies | La Roche Sur Yon | France | 85925 | |
107 | Institut Paoli Calmettes; Oncologie Medicale | Marseille | France | 13273 | |
108 | Institut régional du Cancer Montpellier | Montpellier | France | 34298 | |
109 | Hopital Tenon | Paris | France | 75020 | |
110 | Institut Curie; Oncologie Medicale | Paris | France | 75231 | |
111 | Ico Rene Gauducheau; Oncologie | Saint Herblain | France | 44805 | |
112 | Studienzentrum Aschaffenburg | Aschaffenburg | Germany | 63739 | |
113 | HELIOS Klinikum Berlin-Buch; Klinik für Gynäkologie und Geburtshilfe | Berlin | Germany | 13125 | |
114 | Frauenarzt-Zentrum Zehlendorf an der Teltower Eiche | Berlin | Germany | 14169 | |
115 | Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum | Essen | Germany | 45136 | |
116 | Uniklinik Köln, Klinik und Poliklinik und Geburtshilfe; Brustzentrum Köln | Köln | Germany | 50931 | |
117 | Rotkreuzklinikum München; Frauenklinik | Muenchen | Germany | 80637 | |
118 | Klinikum der Universität München; Campus Großhadern; Klinik und Poliklinik für Frauenheilkunde | Muenchen | Germany | 81377 | |
119 | Gynäkologie Kompetenzzentrum; Praxis Dr. med. Carsten Hielscher | Stralsund | Germany | 18439 | |
120 | Hämatologisch-Onkologische Schwerpunktpraxis Dres. Schlag & Schöttker | Würzburg | Germany | 97080 | |
121 | Grupo Angeles | Guatemala City | Guatemala | 01015 | |
122 | Queen Mary Hospital; Dept of Medicine | Hong Kong | Hong Kong | ||
123 | Szent Margit Hospital; Dept. of Oncology | Budapest | Hungary | 1032 | |
124 | Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika | Budapest | Hungary | 1125 | |
125 | Debreceni Egyetem, Klinikai Kozpont, Onkologiai Klinika | Debrecen | Hungary | 4032 | |
126 | Markusovszky Hospital | Szombathely | Hungary | 9700 | |
127 | Shaare Zedek Medical Center | Jerusalem | Israel | 9103102 | |
128 | Kaplan Medical Center; Oncology Inst. | Rehovot | Israel | 7610001 | |
129 | Tel Aviv Sourasky Medical Ctr; Oncology | Tel Aviv | Israel | 6423906 | |
130 | Ospedale San Carlo; Day Hospital Oncologia Medica | Potenza | Basilicata | Italy | 85100 |
131 | Campus Universitario S.Venuta; Centro Oncologico T.Campanella | Catanzaro | Calabria | Italy | 88100 |
132 | Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica | Napoli | Campania | Italy | 80131 |
133 | IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica | Meldola | Emilia-Romagna | Italy | 47014 |
134 | IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica | Meldola | Emilia-Romagna | Italy | 47014 |
135 | Ospedale Regionale Di Parma; Divisione Di Oncologia Medica | Parma | Emilia-Romagna | Italy | 43100 |
136 | RCCS - Centro di Riferimento; Oncologia Medica B | Aviano (PN) | Friuli-Venezia Giulia | Italy | 33081 |
137 | Azienda Ospedaliero-Universitaria Dipartimento Interaziendale Di Oncologia | Udine | Friuli-Venezia Giulia | Italy | 33100 |
138 | Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1 | Milano | Lombardia | Italy | 20133 |
139 | Istituto Europeo Di Oncologia | Milano | Lombardia | Italy | 20141 |
140 | Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico | Candiolo | Piemonte | Italy | 10060 |
141 | Ospedale Civile; Oncologia Medica | Sassari | Sardegna | Italy | 07100 |
142 | Humanitas Istituto Clinico Catanese S.p.A | Misterbianco (CT) | Sicilia | Italy | 95045 |
143 | A.O. Universitaria Pisana; Oncologia | Pisa | Toscana | Italy | 56100 |
144 | Ospedale Misericordia E Dolce; Oncologia Medica | Prato | Toscana | Italy | 59100 |
145 | Hiroshima University Hospital; Breast Surgery | Hiroshima | Japan | 734-8551 | |
146 | Hyogo Cancer Center; Breast Surgery | Hyogo | Japan | 673-8558 | |
147 | Saitama Medical University International Medical Center; Breast Oncology | Saitama | Japan | 350-1298 | |
148 | Kyungpook National University Medical Center; Oncology | Daegu | Korea, Republic of | 702-210 | |
149 | National Cancer Center | Goyang-si | Korea, Republic of | 10408 | |
150 | Gachon University Gil Medical Center | Incheon | Korea, Republic of | 21565 | |
151 | Seoul National University Hospital | Seoul | Korea, Republic of | 03080 | |
152 | Severance Hospital, Yonsei University Health System | Seoul | Korea, Republic of | 03722 | |
153 | Asan Medical Center | Seoul | Korea, Republic of | 05505 | |
154 | Asan Medical Center | Seoul | Korea, Republic of | 05505 | |
155 | Samsung Medical Center | Seoul | Korea, Republic of | 06351 | |
156 | Consultorio de Medicina Especializada | Mexico | Mexico CITY (federal District) | Mexico | 03100 |
157 | Centro de Investigacion; Clinica Del Pacifico | Acapulco | Mexico | 39670 | |
158 | Instituto Nacional de Cancer | D.f. | Mexico | 14080 | |
159 | Oaxaca Site Management Organization | Oaxaca | Mexico | 68000 | |
160 | Auckland city hospital; Auckland Regional Cancer Centre and Blood Service | Auckland | New Zealand | 1023 | |
161 | Private Health Organization Acibadem Sistina Hospital | Skopje | North Macedonia | 1000 | |
162 | Oslo Universitetssykehus HF; Radiumhospitalet | Oslo | Norway | 0310 | |
163 | Centro Hemato Oncologico Panama | Panama | Panama | 0832 | |
164 | Instituto;Oncologico Miraflores | Lima | Peru | 18 | |
165 | Instituto Nacional de Enfermedades Neoplasicas | Lima | Peru | Lima 34 | |
166 | Cebu Cancer Institute; Perpetual Succour Hospital | Cebu City | Philippines | 6000 | |
167 | Veterans Memorial Medical Ctr; Cancer Research Centre | Quezon City | Philippines | 1101 | |
168 | Cardinal Santos Medical Center | San Juan | Philippines | 1502 | |
169 | Uniwersyteckie Centrum Kliniczne | Gdansk | Poland | ||
170 | Świętokrzyskie Centrum Onkologii; Dział Chemioterapii | Kielce | Poland | 25-734 | |
171 | COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej | Lublin | Poland | 20-090 | |
172 | Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii | Otwock | Poland | 05-400 | |
173 | Wielkopolskie Centrum Onkologii; Oddzial Chemioterapii | Poznan | Poland | 61-866 | |
174 | Wojewódzki Szpital Specjalistyczny Nr 3 | Rybnik | Poland | 44-200 | |
175 | Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie; Klinika Nowotworow Piersi i Chirurgii Rekonstr | Warszawa | Poland | 02-781 | |
176 | Hospital da Luz; Departamento de Oncologia Medica | Lisboa | Portugal | 1500-650 | |
177 | IPO do Porto; Servico de Oncologia Medica | Porto | Portugal | 4200-072 | |
178 | FSBI"National Medical Research Center of Oncology named after N.N.Petrov" MHRF | St Petersburg | Leningrad | Russian Federation | 197758 |
179 | Blokhin Cancer Research Center; Combined Treatment | Moskva | Moskovskaja Oblast | Russian Federation | 115478 |
180 | City Clinical Oncology Hospital | Moscow | Russian Federation | 143423 | |
181 | City Oncology Dispensary | St Petersburg | Russian Federation | ||
182 | SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary | Stavropol | Russian Federation | 355045 | |
183 | Bashkirian Republican Clinical Oncology Dispensary | UFA | Russian Federation | 450054 | |
184 | National University Hospital; National University Cancer Institute, Singapore (NCIS) | Singapore | Singapore | 119228 | |
185 | Institute of Oncology Ljubljana | Ljubljana | Slovenia | 1000 | |
186 | Hospital General Universitario de Elche; Servicio de Oncologia | Elche | Alicante | Spain | 03203 |
187 | Hospital de Jerez de la Frontera; Servicio de Oncologia | Jerez de La Frontera | Cadiz | Spain | 11407 |
188 | Hospital de Donostia; Servicio de Oncologia Medica | San Sebastian | Guipuzcoa | Spain | 20080 |
189 | Hospital Severo Ochoa; Servicio de Oncologia | Leganes | Madrid | Spain | 28911 |
190 | Hospital del Mar; Servicio de Oncologia | Barcelona | Spain | 08003 | |
191 | Hospital Univ Vall d'Hebron; Servicio de Oncologia | Barcelona | Spain | 08035 | |
192 | Hospital Duran i Reynals; Oncologia | Barcelona | Spain | 08907 | |
193 | Hospital San Pedro De Alcantara; Servicio de Oncologia | Caceres | Spain | 10003 | |
194 | Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia | Lerida | Spain | 25198 | |
195 | Hospital General Universitario Gregorio Marañon; Servicio de Oncologia | Madrid | Spain | 28007 | |
196 | Hospital Ramon y Cajal; Servicio de Oncologia | Madrid | Spain | 28034 | |
197 | Hospital Universitario La Paz; Servicio de Oncologia | Madrid | Spain | 28046 | |
198 | Hospital Universitario Virgen del Rocio; Servicio de Oncologia | Sevilla | Spain | 41013 | |
199 | Hospital Universitario Miguel Servet; Servicio Oncologia | Zaragoza | Spain | 50009 | |
200 | Mälarsjukhuset; Onkologkliniken Sörmland | Eskilstuna | Sweden | 63188 | |
201 | Universitätsspital Zürich | Zürich | Switzerland | 8091 | |
202 | National Cheng Kung Uni Hospital; Surgery | Tainan | Taiwan | 704 | |
203 | Chi-Mei Medical Center | Tainan | Taiwan | 736 | |
204 | Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology | Taipei City | Taiwan | 11259 | |
205 | National Taiwan Uni Hospital; Dept of Oncology | Taipei | Taiwan | 100 | |
206 | Chang Gung Memorial Hospital - Linkou | Taoyuan | Taiwan | 333 | |
207 | Bumrungrad International Hosp | Bangkok | Thailand | 10110 | |
208 | Rajavithi Hospital; Division of Medical Oncology | Bangkok | Thailand | 10400 | |
209 | Ninewells Hospital | Dundee | United Kingdom | DD12 9SY | |
210 | Western General Hospital; Clinical Oncology | Edinburgh | United Kingdom | EH4 2XU | |
211 | Diana Princess of Wales Hosp. | Grimsby | United Kingdom | DN33 2BA | |
212 | Royal Lancaster Infirmary, Morecambe Bay Hospitals Nhs Trust | Lancaster | United Kingdom | LA1 4RP | |
213 | Royal Free Hospital; Dept of Oncology | London | United Kingdom | NW3 2QG | |
214 | Christie Hospital NHS Trust | Manchester | United Kingdom | M20 4BX | |
215 | Mount Vernon Hospital | Middlesex | United Kingdom | HA6 2RN | |
216 | Mount Vernon Cancer Centre | Northwood | United Kingdom | HA6 2RN | |
217 | Nottingham City Hospital; Oncology | Nottingham | United Kingdom | NG5 1PB | |
218 | Poole General Hospital | Poole | United Kingdom | BH15 2JB | |
219 | Queen's Hospital; Oncology | Romford | United Kingdom | RM7 0AG | |
220 | Abertawe and Bro Morgannwg NHS Trust; Clinical Researdh Institute | Swansea | United Kingdom | SA6 6NL | |
221 | Royal Cornwall Hospital | Truro | United Kingdom | TR1 3LQ |
Sponsors and Collaborators
- Genentech, Inc.
- Hoffmann-La Roche
Investigators
- Study Director: Clinical Trials, Genentech, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- TDM4529g
- BO25430
- 2010-021067-32